PDS Biotechnology Corporation (NASDAQ: PDSB) kicked off on Monday, down -5.67% from the previous trading day, before settling in for the closing price of $1.41. Over the past 52 weeks, PDSB has traded in a range of $0.85-$4.42.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 6.42%. While this was happening, its average annual earnings per share was recorded 13.59%. With a float of $43.98 million, this company’s outstanding shares have now reached $45.45 million.
Let’s determine the extent of company efficiency that accounts for 24 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
PDS Biotechnology Corporation (PDSB) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of PDS Biotechnology Corporation is 3.78%, while institutional ownership is 18.00%. The most recent insider transaction that took place on Feb 28 ’25, was worth 25,000. In this transaction Director of this company bought 15,060 shares at a rate of $1.66, taking the stock ownership to the 61,213 shares. Before that another transaction happened on Feb 28 ’25, when Company’s Director bought 15,061 for $1.66, making the entire transaction worth $25,001. This insider now owns 78,851 shares in total.
PDS Biotechnology Corporation (PDSB) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.22 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 13.59% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.96% during the next five years compared to 6.42% growth over the previous five years of trading.
PDS Biotechnology Corporation (NASDAQ: PDSB) Trading Performance Indicators
Take a look at PDS Biotechnology Corporation’s (PDSB) current performance indicators. Last quarter, stock had a quick ratio of 2.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.94, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -0.86 in one year’s time.
Technical Analysis of PDS Biotechnology Corporation (PDSB)
Looking closely at PDS Biotechnology Corporation (NASDAQ: PDSB), its last 5-days average volume was 0.42 million, which is a drop from its year-to-date volume of 0.57 million. As of the previous 9 days, the stock’s Stochastic %D was 3.67%.
During the past 100 days, PDS Biotechnology Corporation’s (PDSB) raw stochastic average was set at 35.56%, which indicates a significant increase from 1.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.33% in the past 14 days, which was lower than the 92.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4366, while its 200-day Moving Average is $1.9164. However, in the short run, PDS Biotechnology Corporation’s stock first resistance to watch stands at $1.4000. Second resistance stands at $1.4700. The third major resistance level sits at $1.5100. If the price goes on to break the first support level at $1.2900, it is likely to go to the next support level at $1.2500. Now, if the price goes above the second support level, the third support stands at $1.1800.
PDS Biotechnology Corporation (NASDAQ: PDSB) Key Stats
The company with the Market Capitalisation of 60.79 million has total of 45,710K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -37,610 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -8,490 K.
